Cultivation
Does Your Cannabis Prescription Match the Name on the Label?
Medical cannabis’s cultivar names have, over the past two years, become an increasingly controversial part of the European prescription framework.
Glass Pharms
17stories
27 Octlast updated
More in Glass Pharms
- Cultivation
Are We Underestimating the Pharmaceutical Potential of the Cannabis Plant?
James Duckenfield, CEO of Glass Pharms®, explains why we may be underestimating the pharmaceutical potential of cannabis, and how research, formulation and more controlled delivery could help realise it.
- Opinion
Patients First: What Training the Police Taught Me About Medical Cannabis
As new national guidance instructs officers to treat medical cannabis users as patients first, James Duckenfield, CEO of Glass Pharms, reflects on what training police forces has taught him about the gap between the law and the general understanding of the legal landscape, and how the industry as a whole can help close it.
- Medical Cannabis
Glass Pharms Announces New UK Supply Deals as it launches Premium Range
Glass Pharms, the UK-based cultivator of medical cannabis flower, has announced a supply agreement with Integro Clinic & IPS Pharmacy to provide them with a new premium range of Glass Pharms-branded CBPMs made with domestically grown flower cultivated at the Glass Pharms facility.
- Medical Cannabis
Glass Pharms Signs Supply Agreement With CB1 Pharmacy Offering 3 New Affordable UK-Grown Strains
Glass Pharms has today announced a new supply deal set to see a new line of affordable, entirely UK-produced products enter the market.
- Press releases
Glass Pharms Signs Supply Deal with Mamedica in ‘Milestone for UK Cultivation’
Under the collaboration, Glass Pharms will supply high-quality cannabis flower for use in Mamedica-branded, clinician-prescribed products, reinforcing the value of a fully domestic supply chain for CBPMs (Cannabis-Based Products for Medicinal Use).
- Your #1 Podcast on Cannabis News
Business of Cannabis: Podcast | Releaf x Glass Pharms
The second in our series of guest episodes features a discussion between CEO of Releaf, Tim Kirby, and James Duckenfield, CEO of Glass Pharms.
- Opinion
Incumbent UK Providers Are the ‘Root Cause of the Sector’s Stagnation Since the Legalisation of Medical Cannabis in 2018′
Since the UK legalisation of CBPMs in 2018, the sector has faced slow adoption due to ineffective patient outreach, inconsistent supply chains and variable quality control from other providers.
- Press releases
Medical cannabis could save NHS £4 billion each year
Allowing medical cannabis to be prescribed on the NHS for chronic pain could save the state healthcare provider almost £4 billion annually, according to a new research study.
